Day: September 8, 2021

Paris, September 8, 2021         Quadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer connections through digital and physical channels and one of the largest operators of smart parcel lockers in the world, announced today it has been selected as a finalist once again for the Parcel and Postal Technology International Awards. Its innovative solution Campus Hub is in the 2021 shortlist for the “Final Mile Innovation of the Year” category. Campus Hub is a smart parcel locker solution that enables university campuses to seamlessly manage the growing volume of packages and goods to be delivered and distributed to students. Quadient, a French-based tech player with a strong international footprint, provides businesses with smart software and hardware solutions that enable intelligent communication...

THE INFORMATION CONTAINED HEREIN IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO AUSTRALIA, CANADA, ITALY, DENMARK, JAPAN, THE UNITED STATES, OR TO ANY NATIONAL OF SUCH JURISDICTIONS NBPE Announces Capital Markets Day8 September 2021 NB Private Equity Partners (“NBPE or the “Company”) today announces details of its virtual Capital Markets Day: Date: 30 September 2021 Start: 14:00 BST Finish: 16:00 BST NBPE’s directors and senior portfolio management team will present a detailed update on the portfolio and share their latest views on the private equity environment. Neuberger Berman’s ESG team will also provide insights into NBPE’s sustainable investment capabilities and principles and a portfolio summary. In addition, partners from two private equity firms will present, including case studies of NBPE portfolio companies. This...

WISeKey Announces Appointment of Carlo Schüpp as Chief Operating Officer Mr. Schüpp was the EMEA Practice Leader of Security & Privacy services at Deloitte serving global and European multinationals, and before that he held CIO and CISO positions at Cybertrust and Swift Geneva – September 8, 2021 – WISeKey International Holding (“WISeKey”, SIX: WIHN, NASDAQ: WKEY), a leading cybersecurity and IoT company, today announced appointment of Carlo Schüpp as WISeKey’s Chief Operating Officer, effective immediately. Mr. Schüpp is an entrepreneur located in Belgium with more than three decades of experience and a proven track record in leading digital businesses. Previously, Mr. Schüpp was CEO of Scaled Access, a scale-up pioneering with ecosystem-driven digital transformations. Prior to this, he was the EMEA Practice Leader...

Geneva, Switzerland, September 8, 2021 – Addex Therapeutics (SIX: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference (September 13 – 15, 2021). In his presentation, which is scheduled for Monday, September 13, 2021 at 07:00 ET / 13:00 CEST, Mr Dyer will provide a corporate update and discuss recent developments at Addex. The video presentation will be available for viewing on-demand by registered participants via this link from the time of the presentation and subsequently on the Events page the Company’s website (www.addextherapeutics.com). The video replay will be archived for 90 days following the event. Management will be available for virtual...

Sanofi to acquire Kadmon to further strengthen growth of transplant businessAdds Rezurock™ (belumosudil) an FDA-approved, first-in-class treatment for adult and pediatric patients 12 years and older with chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapyPARIS and NEW YORK – September 8, 2021 – Sanofi has entered into a definitive merger agreement with Kadmon Holdings, Inc. (NASDAQ: KDMN) a biopharmaceutical company that discovers, develops, and markets transformative therapies for disease areas of significant unmet medical needs. The acquisition supports Sanofi’s strategy to continue to grow its General Medicines core assets and will immediately add Rezurock™(belumosudil) to its transplant portfolio. Rezurock is a recently FDA-approved, first-in-class treatment for chronic graft-versus-host...

Pixium Vision expands collaboration with Stanford University on next generation Prima System implantsNew implants to leverage existing PRIMA design and significantly improve implant resolution Collaboration expands existing agreement between Pixium Vision and Stanford UniversityParis, France, September 8, 2021 – 07.00 CET– Pixium Vision SA (Euronext Growth Paris – FR0011950641), a bioelectronics company that develops innovative bionic vision systems to enable patients who have lost their sight to live more independent lives, announces today expansion of collaboration with the academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration (AMD). “We are very excited to be extending our collaboration with Stanford University, with whom...

REGULATED INFORMATION The interim financial report is prepared in accordance with article 13 of the Royal Decree on the obligations of issuers of financial instruments admitted to trading on a regulated market and can be accessed on the website of Bone Therapeutics in the section ‘Financial information’. Bone Therapeutics publishes its interim financial report in English. A French translation of the report will also be made available. In the event of differences between the English and the French version of the report, the original English version will prevail.   Concentrating focus on the continued development and expansion of the mesenchymal stromal cell based allogeneic cell and gene therapy platform Strengthens financial position with the release of the first tranche of EUR 8.0 million as part of the financing agreement with EIB   Management...

UNIONDALE, N.Y., Sept. 08, 2021 (GLOBE NEWSWIRE) — Angion Biomedica Corp. (NASDAQ:ANGN), a late-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases, announced today it is scheduled to host a virtual research and development day focused on its product candidate ANG-3070, a novel, highly selective, and orally-bioavailable small molecule tyrosine kinase receptor inhibitor in clinical development for the treatment of fibrotic diseases, including those in the kidney and lung, at 10:00am EDT on Monday, September 20th. The event will feature presentations by two medical experts, including Joseph V. Bonventre, M.D., Ph.D., Harvard Medical School, who will discuss the current treatment landscape and unmet medical...

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/ TORONTO, Sept. 07, 2021 (GLOBE NEWSWIRE) — Avicanna Inc. (“Avicanna” or the “Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a biopharmaceutical company focused on the development, manufacturing and commercialization of plant-derived cannabinoid-based products, announces the filing of the Company’s unaudited interim financial statements for the three month period ended March 31, 2021, and accompanying management’s discussion and analysis, and related certifications ‎‎(collectively, the “Documents”). Electronic copies of the Documents are available on SEDAR (www.sedar.com) under the Company’s issuer profile. The...